Cached SEC EDGAR filing history for PLUS THERAPEUTICS, INC. (PSTV), most recently a 10-Q dated 2026-05-15. 10 recent filings across 3 form types are indexed, each linked to the structured per-filing render and the EDGAR source. Every figure on this tab is extracted verbatim from the underlying SEC filing — no AI synthesis, no estimation.
← PSTV Overview
8-KMay 15, 20265/15/26
PSTV — 8-K Filing
Track for AlertsPSTV 8-K Summary
On May 15, 2026, PLUS Therapeutics, INC. filed an 8-K covering Results of Operations and Financial Condition (Item 2.02) and Financial Statements and Exhibits (Item 9.01). Primary disclosure: of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act…
8-K Items Disclosed
Item 2.02 — Results of Operations and Financial Condition
Quarterly or annual earnings results released. Often paired with a press release as Exhibit 99.1.
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
Item 9.01 — Financial Statements and Exhibits
Press releases, exhibits, and supporting documents attached to this filing.
99.1
Press Release Announcing Financial Results, dated May 15, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: May 15, 2026 By: /s/ Marc H. Hedrick, M.D. Marc H. Hedrick, M.D.President and Chief Executive Officer
Structured financials are not available for this filing. View the original on SEC EDGAR for details.
Current DredgeCap Risk Profile
8.5/10
HIGH RISK
Dilution Risk
EXTREME9.0/10
Liquidity Risk
HIGH8.0/10
Debt Toxicity
HIGH7.0/10
Profitability Risk
EXTREME9.5/10
Going Concern⚠️ Flagged
The risk profile above reflects the latest cached DredgeCap analysis for PSTV. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open PSTV's company page.
What is a 8-K?
A current report disclosing a material event that occurred between regular reporting periods. Companies are required to file an 8-K within four business days of certain events including earnings releases, executive changes, acquisitions, debt obligations, restructurings, and material agreements. Each 8-K specifies one or more 'Items' identifying which event triggered the filing.
Form-type explainers and 8-K item descriptions are derived from SEC documentation. Financial values are extracted from SEC-tagged XBRL — see the "Source filings" list above each table for direct EDGAR links to every cited filing. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.